Nutra Pharma Operating Expenses Growth & History (NPHC)
Nutra Pharma's operating expenses was $1.7M for fiscal 2025.
View full Nutra Pharma company overviewNutra Pharma annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.7M | $533,222 | +47.37% |
| 2024 | 2024-12-31 | $1.1M | −$157,690 | −12.29% |
| 2023 | 2023-12-31 | $1.3M | −$872,992 | −40.48% |
| 2022 | 2022-12-31 | $2.2M | $159,514 | +7.99% |
| 2021 | 2021-12-31 | $2.0M | $1.1M | +112.47% |
| 2020 | 2020-12-31 | $939,863 | −$324,745 | −25.68% |
| 2019 | 2019-12-31 | $1.3M | −$628,316 | −33.19% |
| 2018 | 2018-12-31 | $1.9M | $416,908 | +28.25% |
| 2017 | 2017-12-31 | $1.5M | −$512,852 | −25.79% |
| 2016 | 2016-12-31 | $2.0M | −$4.0M | −66.81% |
| 2015 | 2015-12-31 | $6.0M | $3.3M | +123.36% |
| 2014 | 2014-12-31 | $2.7M | $257,371 | +10.61% |
| 2013 | 2013-12-31 | $2.4M | −$231,634 | −8.72% |
| 2012 | 2012-12-31 | $2.7M | −$573,853 | −17.76% |
| 2011 | 2011-12-31 | $3.2M | −$981,292 | −23.30% |
| 2010 | 2010-12-31 | $4.2M | — | — |
Nutra Pharma quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $468,089 | $114,132 | +32.24% |
| Q1 2026 | 2026-03-31 | $398,224 | −$10,726 | −2.62% |
| Q4 2025 | 2025-12-31 | $475,407 | $209,952 | +79.09% |
| Q3 2025 | 2025-09-30 | $420,652 | $165,207 | +64.67% |
| Q2 2025 | 2025-06-30 | $353,957 | $79,619 | +29.02% |
| Q1 2025 | 2025-03-31 | $408,950 | $78,444 | +23.73% |
| Q4 2024 | 2024-12-31 | $265,455 | $31,494 | +13.46% |
| Q3 2024 | 2024-09-30 | $255,445 | −$25,304 | −9.01% |
| Q2 2024 | 2024-06-30 | $274,338 | $7,399 | +2.77% |
| Q1 2024 | 2024-03-31 | $330,506 | −$171,279 | −34.13% |
| Q4 2023 | 2023-12-31 | $233,961 | −$930,908 | −79.92% |
| Q3 2023 | 2023-09-30 | $280,749 | −$23,925 | −7.85% |
| Q2 2023 | 2023-06-30 | $266,939 | −$103,728 | −27.98% |
| Q1 2023 | 2023-03-31 | $501,785 | $185,569 | +58.68% |
| Q4 2022 | 2022-12-31 | $1.2M | $707,646 | +154.77% |
| Q3 2022 | 2022-09-30 | $304,674 | −$217,258 | −41.63% |
| Q2 2022 | 2022-06-30 | $370,667 | −$89,498 | −19.45% |
| Q1 2022 | 2022-03-31 | $316,216 | −$241,376 | −43.29% |
| Q4 2021 | 2021-12-31 | $457,223 | $111,747 | +32.35% |
| Q3 2021 | 2021-09-30 | $521,932 | $327,913 | +169.01% |
| Q2 2021 | 2021-06-30 | $460,165 | $258,738 | +128.45% |
| Q1 2021 | 2021-03-31 | $557,592 | $358,651 | +180.28% |
| Q4 2020 | 2020-12-31 | $345,476 | −$39,561 | −10.27% |
| Q3 2020 | 2020-09-30 | $194,019 | −$76,630 | −28.31% |
| Q2 2020 | 2020-06-30 | $201,427 | −$132,860 | −39.74% |
| Q1 2020 | 2020-03-31 | $198,941 | −$75,694 | −27.56% |
| Q4 2019 | 2019-12-31 | $385,037 | $65,654 | +20.56% |
| Q3 2019 | 2019-09-30 | $270,649 | −$590,159 | −68.56% |
| Q2 2019 | 2019-06-30 | $334,287 | −$14,373 | −4.12% |
| Q1 2019 | 2019-03-31 | $274,635 | −$89,438 | −24.57% |
| Q4 2018 | 2018-12-31 | $319,383 | $15,453 | +5.08% |
| Q3 2018 | 2018-09-30 | $860,808 | $553,576 | +180.18% |
| Q2 2018 | 2018-06-30 | $348,660 | −$88,963 | −20.33% |
| Q1 2018 | 2018-03-31 | $364,073 | −$63,158 | −14.78% |
| Q4 2017 | 2017-12-31 | $303,930 | −$105,087 | −25.69% |
| Q3 2017 | 2017-09-30 | $307,232 | −$259,346 | −45.77% |
| Q2 2017 | 2017-06-30 | $437,623 | −$191,126 | −30.40% |
| Q1 2017 | 2017-03-31 | $427,231 | $42,707 | +11.11% |
| Q4 2016 | 2016-12-31 | $409,017 | −$182,318 | −30.83% |
| Q3 2016 | 2016-09-30 | $566,578 | −$3.4M | −85.68% |
| Q2 2016 | 2016-06-30 | $628,749 | −$425,800 | −40.38% |
| Q1 2016 | 2016-03-31 | $384,524 | −$4,208 | −1.08% |
| Q4 2015 | 2015-12-31 | $591,335 | −$346,293 | −36.93% |
| Q3 2015 | 2015-09-30 | $4.0M | $3.2M | +429.39% |
| Q2 2015 | 2015-06-30 | $1.1M | $331,854 | +45.92% |
| Q1 2015 | 2015-03-31 | $388,732 | $114,044 | +41.52% |
| Q4 2014 | 2014-12-31 | $937,628 | −$200,839 | −17.64% |
| Q3 2014 | 2014-09-30 | $747,468 | $170,368 | +29.52% |
| Q2 2014 | 2014-06-30 | $722,695 | $360,304 | +99.42% |
| Q1 2014 | 2014-03-31 | $274,688 | −$72,462 | −20.87% |
| Q4 2013 | 2013-12-31 | $1.1M | −$370,481 | −24.55% |
| Q3 2013 | 2013-09-30 | $577,100 | $363,113 | +169.69% |
| Q2 2013 | 2013-06-30 | $362,391 | $166,409 | +84.91% |
| Q1 2013 | 2013-03-31 | $347,150 | −$390,675 | −52.95% |
| Q4 2012 | 2012-12-31 | $1.5M | $672,787 | +80.46% |
| Q3 2012 | 2012-09-30 | $213,987 | −$618,292 | −74.29% |
| Q2 2012 | 2012-06-30 | $195,982 | −$659,197 | −77.08% |
| Q1 2012 | 2012-03-31 | $737,825 | $30,849 | +4.36% |
| Q4 2011 | 2011-12-31 | $836,161 | — | — |
| Q3 2011 | 2011-09-30 | $832,279 | −$114,311 | −12.08% |
| Q2 2011 | 2011-06-30 | $855,179 | −$594,319 | −41.00% |
| Q1 2011 | 2011-03-31 | $706,976 | — | — |
| Q3 2010 | 2010-09-30 | $946,590 | — | — |
| Q2 2010 | 2010-06-30 | $1.4M | — | — |
Nutra Pharma operating expenses trends
Over the last five fiscal years, Nutra Pharma's operating expenses increased from $939,863 to $1.7M, a change of $719,103. The latest reported quarter, Q2 2026, shows $468,089.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nutra Pharma source filings ↗